Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Photo Dynamic Therapy and Therapeutic Laser Technology. The company also designs, manufactures, and distributes super-pulsed cool laser technology for the treatment of pain for knees, nerves, muscles, and joints, as well as for in off-label use. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories. The company is also developing TLD-1433, an anti-cancer drug, which is in Phase 1B clinical trial for non-muscle invasive bladder cancer. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.